Sanctuary Advisors LLC Invests $228,000 in Envista Holdings Co. (NYSE:NVST)

Sanctuary Advisors LLC bought a new position in shares of Envista Holdings Co. (NYSE:NVST) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 10,631 shares of the company’s stock, valued at approximately $228,000.

Several other large investors have also bought and sold shares of NVST. Nuance Investments LLC boosted its holdings in shares of Envista by 47.2% during the second quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock worth $117,048,000 after purchasing an additional 2,256,993 shares during the period. Sei Investments Co. lifted its stake in shares of Envista by 20.4% in the second quarter. Sei Investments Co. now owns 925,170 shares of the company’s stock worth $15,386,000 after buying an additional 157,048 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of Envista in the second quarter worth about $7,019,000. Diamond Hill Capital Management Inc. grew its stake in shares of Envista by 8.1% in the third quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company’s stock worth $26,394,000 after acquiring an additional 100,360 shares during the last quarter. Finally, Pacer Advisors Inc. raised its holdings in Envista by 22.2% in the 3rd quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock valued at $69,749,000 after acquiring an additional 642,401 shares in the last quarter.

Envista Stock Performance

NYSE:NVST opened at $19.24 on Monday. The company has a market capitalization of $3.31 billion, a P/E ratio of -2.48, a P/E/G ratio of 2.71 and a beta of 1.31. Envista Holdings Co. has a 1 year low of $15.15 and a 1 year high of $25.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The business has a fifty day simple moving average of $20.22 and a two-hundred day simple moving average of $18.46.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The firm had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. During the same period in the previous year, the business earned $0.43 EPS. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. On average, analysts expect that Envista Holdings Co. will post 0.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and increased their price objective for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Evercore ISI boosted their price objective on Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Stifel Nicolaus lifted their price objective on Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Robert W. Baird boosted their price target on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. Finally, Mizuho initiated coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target for the company. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Envista presently has a consensus rating of “Hold” and a consensus price target of $20.65.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.